• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Abbott launches Lingo OTC CGM in Walgreens

December 17, 2025 By Sean Whooley

Abbott Lingo over-the-counter CGM next to packaging
The Lingo over-the-counter CGM. [Image courtesy of Abbott]
Abbott (NYSE:ABT) announced today that it made its Lingo over-the-counter continuous glucose monitor (CGM) available at Walgreens.

People can purchase the Lingo biosensor both in Walgreens brick-and-mortar stores and online. This marks the latest expansion for Lingo as it penetrates different markets, starting with a launch through Amazon as its first retail agreement for the device earlier this year, then with Walmart as the first brick-and-mortar retailer for the CGM.

Earlier this month, Abbott unveiled Lingo compatibility with Android devices as well.

Lingo features a biosensor and mobile app designed for customers who want to improve their overall health and wellness. The company built Lingo on its FreeStyle Libre CGM technology platform. The consumer biowearable is available for consumers 18 years and older not on insulin. It tracks glucose in real time and provides personal insights and coaching. The company designed it to help people build healthy habits, retain their metabolism and improve their overall well-being.

Abbott received FDA clearance for Lingo and its Libre Rio OTC CGMs in June 2024. Lingo is one of two OTC CGMs on the market, with Dexcom’s Stelo also an option for those seeking to monitor glucose levels.

Read more about Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Visit here to purchase our Medtech Market Special Report on CGMs.

According to Abbott, 78% of Americans live within five miles of a Walgreens. This launch makes it easier for people to find innovative health tools and fit them into their daily lives.

The company said its rollout reflects strong consumer interest in metabolic health and more approachable ways to take early action. This rings especially true for prediabetes as people look for ways to understand their health. Abbott said a new study published in The Lancet Diabetes & Endocrinology found that people with prediabetes who return their glucose levels to normal can cut their risk of cardiovascular death or hospitalization for heart failure by 50% over two decades.

“Prediabetes affects nearly 100 million U.S. adults, and most don’t know they’re at risk,” said Olivier Ropars, divisional VP of Abbott’s Lingo business. “Understanding how your body responds to food, stress, and movement is an important first step. Lingo gives people real-time glucose insights they can use to make small, informed changes that support better metabolic health. Making Lingo available through Walgreens brings that capability to so many more people.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott

IN CASE YOU MISSED IT

  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance
  • Medtronic moves to divest final stake in MiniMed
  • Dexcom adds former Stryker CFO to board
  • MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS